Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
News & Analysis: Blueprint Medicines
Investors have run back to the stock after promising clinical results.
BPMC earnings call for the period ending June 30, 2019.
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
It looks like this biotech has what big-pharma companies have been eager to acquire.
Here's why these very different drugmakers could both receive a big buyout offer before the end of 2019.
These cancer drug developers could report market-moving news soon.
BPMC earnings call for the period ending March 31, 2019.
Find out why these oncology-focused companies stand out as great opportunities right now.
BPMC earnings call for the period ending December 31, 2018.